EMA Recommends Rasonque for Metastatic Pancreatic Cancer
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the marketing authorisation of Rasonque (daraxonrasib) for the treatment of adults with metastatic pancreatic adenocarcinoma whose disease has progressed after at least one prior systemic treatment.
Addressing an Unmet Medical Need
Metastatic pancreatic adenocarcinoma is an aggressive form of cancer characterized by poor prognosis and limited treatment options, especially after initial therapies fail. Standard chemotherapy regimens often provide limited efficacy and are associated with significant toxicity, underscoring the urgent need for novel therapeutic options.
Rasonque, an oral RAS inhibitor, represents a targeted approach to this challenging disease. RAS proteins regulate cell growth and survival, and mutations in the RAS gene—particularly the G12 mutation—are common drivers of pancreatic cancer progression. Daraxonrasib works by binding to cyclophilin A, forming a complex that inhibits RAS protein activity, thereby inducing cancer cell death and slowing tumor growth.
Accelerated Evaluation Through Phased Review
The EMA employed a phased review process for Rasonque, allowing the CHMP to begin evaluating submitted data in stages starting in July 2026, months before the full application was completed. This innovative approach reduced the assessment timeline to under 150 days, compared to the typical 210 active days and approximately one year in total for standard evaluations.
This phased review model aligns with the EU’s new pharmaceutical legislation aimed at streamlining medicine evaluations to facilitate earlier patient access to promising therapies. The positive outcome of Rasonque’s phased review may serve as a precedent for future assessments of high-priority medicines.
Clinical Trial Evidence
The recommendation is based on results from a multinational, open-label phase 3 clinical trial involving 500 patients with metastatic pancreatic adenocarcinoma who had experienced disease progression after prior systemic treatment. Notably, 92% of participants carried confirmed RAS G12 mutations.
Key findings include:
- Median overall survival was 12.4 months for patients treated with Rasonque versus 6.7 months for those receiving chemotherapy.
- Median progression-free survival was 7.2 months with Rasonque compared to 3.6 months with chemotherapy.
These results demonstrate a substantial improvement in both survival and disease control for patients treated with daraxonrasib.
Safety Profile
The most commonly reported adverse events associated with Rasonque were diarrhea, rash, stomatitis (inflammation of the mouth lining), nausea, and vomiting. The safety profile was considered manageable in the context of the disease and treatment benefits.
Next Steps Towards Patient Access
Following the CHMP’s positive opinion, the recommendation will be forwarded to the European Commission for a final decision on granting marketing authorisation across the European Union. If approved, individual EU member states will determine pricing and reimbursement policies based on their national healthcare frameworks.
Future Implications
The EMA and CHMP plan to continue utilizing phased reviews for other medicines that address unmet medical needs and hold significant public health interest. This approach is expected to enhance regulatory agility and expedite patient access to innovative therapies, particularly in oncology.
Conclusion
The EMA’s recommendation for Rasonque marks a promising advancement in the treatment landscape for metastatic pancreatic adenocarcinoma, offering hope for improved outcomes in a patient population with limited options. The use of phased review exemplifies regulatory innovation aimed at accelerating access to critical medicines while maintaining rigorous standards for safety and efficacy.